Abstract
Prevention of residual paralysis depends on judicious neuromuscular blockade management, monitoring, and use of reversal
agents. Administration of anticholinesterase agents is particularly problematic in patients with cardiac diseases. Thus, the use
of neostigmine should be individualized based on a risk/benefit analysis.Clinical data suggest that sugammadex is the drug of
choice for the reversal of neuromuscular blockade in the patient with cardiac disease.
Keywords
Full Text:
References
deBacker J, Hart N, Fan E. Neuromuscular Blockade in the 21st Century Management of the Critically III
Patient. Chest 2017;151:697–706.
Brull SJ, Kopman AF. Current Status of Neuromuscular Reversal and Monitoring: Challenges and Opportunities. Anesthesiology 2017;126:173–190.
Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and
adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120–8.
Donati F. Residual paralysis: a real problem or did we invent a new disease? Can J Anaesth.2013;60:714–29.
Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009;103:115–29.
Kizilay D, Dal D, Saracoglu KT, Eti Z, Gogus FY. Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. J Clin Anesth 2016;28:30-5.
Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous neostigmine in two heart transplant
recipients. Anesth Analg. 1994;78:779–82.
Sawasdiwipachai P, Laussen PC, McGowan FX, Smoot L, Casta A. Cardiac arrest after neuromuscular
blockade reversal in a heart transplant infant. Anesthesiology. 2007;107:663–5.
Backman SB, Fox GS, Stein RD, Ralley FE. Neostigmine decreases heart rate in heart transplant patients. Can J Anaesth. 1996;43:373–8.
Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex
for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874–84.
Bertolizio G, Yuki K, Odegard K, Collard V, Dinardo J. Cardiac arrest and neuromuscular blockade reversal
agents in the transplanted heart. J Cardiothorac Vasc Anesth. 2013;27:1374–8.
Monaco F, Oriani A, De Luca M, Bignami E, Sala A, Chiesa R, Melissano G, Zangrillo A. Thoracic aorta
aneurysm open repair in heart transplant recipient; the anesthesiologist’s perspective. Ann Card Anaesth. 2016;19:201–4.
Bjerke RJ, Mangione MP. Asystole after intravenous neostigmine in a heart transplant recipient. Can J
Anaesth. 2001;48:305–7.
Blasco LM, Parameshwar J, Vuylsteke A. Anaesthesia for noncardiac surgery in the heart transplant recipient. Curr Opin Anaesthesiol. 2009;22:109–13.
Gómez-Ríos M, López LR. Use of combination of rocuronium and sugammadex in heart transplant
recipients. Anaesth Intensive Care 2012;40:903–4.
Sengul T, Saracoglu A, Sener S, Bezen O. The use of sugammadex in a pregnant patient with Wolff-Parkinson-White syndrome. J Clin Anesth. 2016;33:1–4.
Kies SJ, Pabelick CM, Hurley HA, White RD, Ackerman MJ. Anesthesia for patients with congenital long QT
syndrome. Anesthesiology 2005;102:204–10.
Olthoff D, Deutrich C, Lindenau KF. [Effects of atropine in coronary heart disease]. Anasth Intensivther
Notfallmed. 1988;23:256–9.
de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Reversal of profound rocuronium neuromuscular
blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology. 2006;104:718–23.
Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine
for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016;35:1–12.
Keating GM. Sugammadex: A Review of Neuromuscular Blockade Reversal. Drugs. 2016;76:1041–52.
Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24:29–35.
Brull SJ, Naguib M. Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.
Drug Des Devel Ther. 2009;3:119–29.
de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30:599–611.
Cammu G, Coart D, De Graeve K, Beelen R. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Acta Anaesthesiol Belg. 2012;63(2):69–73.
Keating GM. Sugammadex: A Review of Neuromuscular Blockade Reversal. Drugs. 2016.
Refbacks
- There are currently no refbacks.